all

The National Lipid Association ("NLA") plays an important role in reaching out to healthcare professionals, patients, and other groups. Our members guide research, discover new therapies, and engage in high quality medical practice.

The NLA offers educational opportunities that help translate scientific and medical progress into the efficient delivery of effective medical care, develops resources that guide our members in advancing medical care, and provides a forum for presenting new skills and scientific developments.

Further analysis from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial was presented on November 15, 2011, at the American Heart Association (AHA) 2011 Scientific Sessions.

Abstract: With an occurrence of approximately 1 in 500 individuals worldwide, the heterozygous form of familial hypercholesterolemia is not uncommon. With statins being contraindicated in pregnancy (Category X), the management of pregnant women who carry this diagnosis has not been clearly defined. This case series describes five pregnant women seen at the Emory Center for Heart Disease Prevention between 2004 and 2010 who carried this diagnosis, their treatment, and subsequent outcomes.